BD Partners with University of Pennsylvania to Enhance Immune Profiling Research and Therapies
- Becton Dickinson (BD) partners with the University of Pennsylvania to advance immune profiling and immune-mediated therapies.
- BD will provide instrumentation and tools for a 1,000-patient immune profiling study starting in summer 2026.
- The collaboration highlights BD's commitment to healthcare innovation and developing targeted therapies through advanced technology.
BD Partners with University of Pennsylvania to Advance Immune Profiling Research
Becton, Dickinson and Company (BD) announces a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, focusing on deep human immune profiling and the advancement of immune-mediated therapies. This partnership aims to create and validate an innovative high-parameter flow cytometry panel that will analyze over 30 cellular characteristics, including pivotal phosphorylation markers. The initiative is crucial in understanding cellular responses to various drugs and disease states, which can lead to the development of targeted therapies. Central to this collaboration is the BD FACSDiscover™ A8 Cell Analyzer, a state-of-the-art tool that will play a significant role in an upcoming 1,000-patient immune profiling study, scheduled to begin in the summer of 2026 with the Penn Colton Center for Autoimmunity.
The collaboration emphasizes the synergistic potential of merging academic research with industrial capabilities. BD will provide its instrumentation, reagents, software, and informatics, while the I3H team will spearhead the scientific and clinical research aspects. This partnership not only showcases BD's commitment to innovation in immunotherapy but also underscores the importance of collaborative efforts in translating scientific discoveries into practical medical applications. Dr. E. John Wherry from I3H highlights the initiative's goal of unlocking the intricacies of the human immune system, which could significantly accelerate the development of precise and effective medical treatments.
Anticipated outcomes from this collaboration include the publication of findings in a peer-reviewed manuscript, contributing to the broader scientific community’s understanding of immune responses. This innovative approach holds great promise for enhancing therapeutic strategies and advancing the field of immunotherapy. The partnership reflects BD's ongoing dedication to pioneering advancements in healthcare through cutting-edge technology and collaborative research, positioning the company at the forefront of immunological studies.
In addition to this collaboration, BD continues to explore other avenues in healthcare innovation, focusing on enhancing diagnostic and therapeutic solutions. The company's commitment to advancing medical technology is evident in its ongoing research initiatives and partnerships across various institutions and healthcare organizations. By fostering such collaborations, BD aims to drive forward the next generation of medical treatments and improve patient outcomes globally.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

